Aurora plans to take advantage of a new regulatory pathway announced by Food and Drug Administration officials Marty Makary and Vinay Prasad in the fall. The new program, called the “plausible mechanism pathway,” allows the FDA to approve personalized treatments for rare and fatal diseases based on data from just a handful of patients, according to Makary and Prasad in a New England Journal of Medicine article.